Sonoma Pharmaceuticals Inc

Amendment to Bylaws

On June 14, 2024, the Board of Directors approved an amendment to Section 2.8 of our Amended and Restated Bylaws, changing our stockholders’ meeting quorum requirement from the holders of a majority of the stock issued and outstanding and entitled to vote, present in person or represented in proxy, to “the holders of at least one-third of the stock issued and outstanding and entitled to vote, present in person or represented in proxy.”

A copy of Amendment No. 1 to the Amended and Restated Bylaws of Sonoma Pharmaceuticals, Inc., as adopted by the Board of Directors, is filed as Exhibit 3.10 to this Annual Report on Form 10-K.

Equity Awards

On June 14, 2024, the Compensation Committee of the Board of Directors approved an equity award of 53,586 Restricted Stock Units to each of Ms. Trombly, Mr. Dvonch and Mr. Thornton, to be issued on June 20, 2024, at a valuation based on the five day weighted-average stock price prior to the date of grant.

During the quarter ended March 31, 2024, no director or officer adopted orterminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.